
China Approves World’s First CAR T-Cell Therapy for Solid Tumors
Regulators in China have granted approval for satricabtagene autoleucel, or satri-cel, marking the first time a CAR T-cell therapy has been cleared globally for the treatment of solid tumors. The therapy targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have exhausted standard treatment options.













.jpg)







:max_bytes(150000):strip_icc():focal(999x0:1001x2)/ted-danson-oceana-081624-tout-e6bc00c561ec488881fa53ab91e7c18d.jpg)




